Clinical Trial Update: A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study of ibrutinib in pediatric and young adult relapsed or refractory mature B-cell non-Hodgkin lymphoma was terminated; results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mature B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Lymphoma, Non-Hodgkin | Phase 3 | Status: TERMINATED | Results posted: 2022-12-02